View on market: Stay Cautious, be with quality business:

Asian stocks were mixed early Wednesday and Treasuries trimmed a rally as traders awaited inflation readings from China and the U.S. Shares fluctuated in Japan, edged up in Australia and fell in South Korea. U.S. futures slipped after the S&P 500 dipped for the first time in nine sessions, hurt by financial shares. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, shed 0.62% to 17,968.50, as of 8:10 a.m. Oil extended an advance toward $85 a barrel on speculation that the Biden administration may pull the plug on any plans to release crude from the nation’s emergency reserves after a U.S. energy report showed supplies rising next year.

Economic Calender:

  • INR: CPI (YoY) (Oct) on 12th November, 2021.
  • INR: Manufacturing Output (MoM) (Sep) on 12th November, 2021.
  • USD: Core CPI (MoM) (Oct) on 10th November, 2021.
  • USD: Crude Oil Inventories on 10th November, 2021.

Earnings: Pidilite Industries, Zomato, Oil India, Bank of Baroda, Berger Paints India, Birla Corporation, Crisil, Gujarat Fluorochemicals, Metropolis Healthcare, Alembic Pharmaceuticals, Glenmark Life Sciences, Narayana Hrudayalaya, NIIT, Nuvoco Vistas Corporation, Rail Vikas Nigam, Firstsource Solutions, Affle (India), India Cements, Mazagon Dock Shipbuilders, RCF, Marksans Pharma, EPL, Equitas Holdings, Eveready Industries India, Filatex India, Galaxy Surfactants, GE T&D India, General Insurance Corporation of India, Hawkins Cookers, Hemisphere Properties India, Indostar Capital Finance, Jamna Auto Industries, Kalyan Jewellers India, Krishna Institute of Medical Sciences, KSB, MOIL, NGL Fine-Chem, Paisalo Digital, Sansera Engineering, Strides Pharma Science, Suprajit Engineering, Timken India, Tata Teleservices (Maharashtra), Vinati Organics.


Power Grid Corporation of India Q2FY22 (Consolidated, YoY): Revenue up 8% at Rs 10,266.98 crore Vs Rs 9,529.68 crore Net profit up 9% at Rs 3,376.38 crore Vs Rs 3,094.10 crore Ebitda up 8% at Rs 9,110.54 crore Vs Rs 8,441.41 crore Margin at 88.7% Vs 88.6%.

Indraprastha Gas Q2FY22 (Consolidated, YoY): Revenue up 40% at Rs 2,015.99 crore Vs Rs 1,440.74 crore Net profit up 10% at Rs 418.63 crore Vs Rs 380.45 crore Ebitda up 30% at Rs 530.18 crore Vs Rs 407.12 crore Margins at 26.3% Vs 28.3%.

International Markets:

U.S & Europe

Particulars 9th Nov Chg Chg(%)
Nasdaq 15,886.54 -95.82 -0.60
Dow 36,319.98 -112.24 -0.31
FTSE 7,274.04 -26.36 -0.36
CAC 7,043.27 -4.21 -0.06
DAX 16,040.47 -6.05 -0.04
Dow Fut.* 36,128.00 81.00 -0.22

Asian markets:

Particulars 10th Nov Chg Chg(%)
SGX Nifty 17,968.50 -111.50 -0.62
Nikkei 29,200.31 -85.15 -0.29
Straits Times 3,223.42 -20.00 -0.62
Hang Seng 24,739.55 -73.58 -0.30
Shanghai 3,471.60 -35.40 -1.01

ADR Watch:

Particulars 9th Nov Chg Chg(%)
Dr Reddy 64.66 -0.17 -0.26
HDFC Bank 72.11 0.13 0.18
ICICI Bank 21.11 0.07 0.33
Infosys 23.30 -0.14 -0.60
Tata Motor 33.61 -0.47 -1.38
Wipro 9.08 -0.12 -1.30

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR 74.04 0.03
Brent 85.08 -0.07
Gold 1830.25 -0.03
Silver 24.328 0.04


Particulars 9th Nov 8th Nov
FIIs -860.65 -860.65
DIIs 1911.77 1911.77

Brokerage Radar:

CLSA ON AUROBINDO PHARMA: Maintain buy at the price of Rs 677 for the target price of Rs 830. Profit fell 13% YOY & is 5% below their estimate US revenue surprised positively & grew 11% QoQ. ARV sales saw another quarter with a sharp decline R&D efforts towards dvpt of high-entry-barrier pdts progressing well. Lower their FY22-24 EPS estimates by 2-4%.

JEFFERIES ON IGL: Maintain buy at the price of Rs 494 for the target price of Rs 660. Sharp beat in EBITDA margin is impressive leading to a 13% EBITDA beat. Near-term volume outlook will be helped by re opening. Build in a near double-digit volume CAGR over FY 20-24 expect co to maintain margin amid rising APM gas costs ahead.

News Update:

Adani Green Energy: has set a target of achieving 45 GW renewable energy capacity by 2030, with the average tariff below the average power purchase cost at the national level. The company will also invest $20 billion in renewable energy development over the next decade and develop a 2 GW per year solar manufacturing capacity by FY23. Adani Transmission, which distributes electricity in parts of Mumbai, is on course to increase the share of renewables in its power procurement to 30% by FY23 & to 70% by FY30 from current 3%.

Cipla: The Company’s unit Cipla Technologies LLC will continue to reimburse Pulmatrix Inc for 50% of all third-party costs for the development of Pulmazole, which would include 40% of dedicated personnel and consulting costs and another 10% upon the timely achievement of certain development milestones. Pulmatrix has also granted Cipla Technologies exclusive rights to develop and sell Pulmazole in India, Nepal, Yemen, Iran, South Africa, Sri Lanka, Myanmar and Algeria for 2% royalties on net sales.

IDFC: Board, as part of simplification of corporate structure, has approved the merger of IDFC Alternatives, IDFC Trustee Company and IDFC Projects into IDFC subject to regulatory approvals from various authorities, as applicable.

Dixon Technologies (India): The company has entered into joint venture agreement with Beetel Teletech for manufacturing of telecom and networking products. The JV company Dixon Electro Appliances will be 51% owned by Dixon and 49% owned by Beetel

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL